At CombiGene’s Annual General Meeting, Gunilla Lundmark was elected as new member of the Board of Directors. Gunilla is an entrepreneur through and through, and has 25 years of experience from leading positions in the life science industry. Gunilla's successful entrepreneurship was manifested in 2014 in the “2014 BioTech Builder Prize”. Gunilla is the CEO of Uppsala University Invest AB since 2018 and has previously held a number of leading positions at companies such as Pharmanest AB and Q-Med AB.
“Gunilla's long experience of the life science industry and her stated entrepreneurial skills will mean a lot to the continued development of CombiGene,” CombiGene Chairman Bert Junno comments.
“I am very much looking forward to being part of CombiGene's Board of Directors. I'm impressed with the company's work so far. CombiGene has a very exciting and promising time ahead of it, not least in the epilepsy project that is approaching the first study in humans,” says Gunilla Lundmark.